BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Togarsimalemath SK, Sethi SK, Duggal R, Le Quintrec M, Jha P, Daniel R, Gonnet F, Bansal S, Roumenina LT, Fremeaux-Bacchi V, Kher V, Dragon-Durey MA. A novel CFHR1-CFHR5 hybrid leads to a familial dominant C3 glomerulopathy. Kidney Int 2017;92:876-87. [PMID: 28729035 DOI: 10.1016/j.kint.2017.04.025] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
Number Citing Articles
1 Rodríguez de Córdoba S. Genetic variability shapes the alternative pathway complement activity and predisposition to complement‐related diseases. Immunological Reviews. [DOI: 10.1111/imr.13131] [Reference Citation Analysis]
2 Tschernoster N, Erger F, Walsh PR, McNicholas B, Fistrek M, Habbig S, Schumacher AL, Folz-Donahue K, Kukat C, Toliat MR, Becker C, Thiele H, Kavanagh D, Nürnberg P, Beck BB, Altmüller J. Unraveling Structural Rearrangements of the CFH Gene Cluster in Atypical Hemolytic Uremic Syndrome Patients Using Molecular Combing and Long-Fragment Targeted Sequencing. J Mol Diagn 2022;24:619-31. [PMID: 35398599 DOI: 10.1016/j.jmoldx.2022.02.006] [Reference Citation Analysis]
3 Li X, Zong J, Si S. Complement Factor H related protein 1 and immune inflammatory disorders. Molecular Immunology 2022;145:43-9. [DOI: 10.1016/j.molimm.2022.03.117] [Reference Citation Analysis]
4 Piras R, Breno M, Valoti E, Alberti M, Iatropoulos P, Mele C, Bresin E, Donadelli R, Cuccarolo P, Smith RJH, Benigni A, Remuzzi G, Noris M. CFH and CFHR Copy Number Variations in C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis. Front Genet 2021;12:670727. [PMID: 34211499 DOI: 10.3389/fgene.2021.670727] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5 Poppelaars F, Goicoechea de Jorge E, Jongerius I, Baeumner AJ, Steiner MS, Józsi M, Toonen EJM, Pauly D; SciFiMed consortium. A Family Affair: Addressing the Challenges of Factor H and the Related Proteins. Front Immunol 2021;12:660194. [PMID: 33868311 DOI: 10.3389/fimmu.2021.660194] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
6 Malik TH, Gitterman DP, Lavin DP, Lomax-Browne HJ, Hiemeyer EC, Moran LB, Boroviak K, Cook HT, Gilmore AC, Mandwie M, Ahmad A, Alexander IE, Logan GJ, Marchbank KJ, Bradley A, Pickering MC. Gain-of-function factor H-related 5 protein impairs glomerular complement regulation resulting in kidney damage. Proc Natl Acad Sci U S A 2021;118:e2022722118. [PMID: 33753502 DOI: 10.1073/pnas.2022722118] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
7 Ahmad SB, Bomback AS. C3 Glomerulopathy: Pathogenesis and Treatment. Adv Chronic Kidney Dis 2020;27:104-10. [PMID: 32553242 DOI: 10.1053/j.ackd.2019.12.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
8 Zipfel PF, Wiech T, Stea ED, Skerka C. CFHR Gene Variations Provide Insights in the Pathogenesis of the Kidney Diseases Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy. J Am Soc Nephrol 2020;31:241-56. [PMID: 31980588 DOI: 10.1681/ASN.2019050515] [Cited by in Crossref: 20] [Cited by in F6Publishing: 28] [Article Influence: 10.0] [Reference Citation Analysis]
9 Levine AP, Chan MMY, Sadeghi-Alavijeh O, Wong EKS, Cook HT, Ashford S, Carss K, Christian MT, Hall M, Harris CL, McAlinden P, Marchbank KJ, Marks SD, Maxwell H, Megy K, Penkett CJ, Mozere M, Stirrups KE, Tuna S, Wessels J, Whitehorn D, Johnson SA, Gale DP; MPGN/DDD/C3 Glomerulopathy Rare Disease Group., NIHR BioResource. Large-Scale Whole-Genome Sequencing Reveals the Genetic Architecture of Primary Membranoproliferative GN and C3 Glomerulopathy. J Am Soc Nephrol 2020;31:365-73. [PMID: 31919107 DOI: 10.1681/ASN.2019040433] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
10 Sugawara Y, Kato H, Yoshida Y, Fujisawa M, Kokame K, Miyata T, Akioka Y, Miura K, Hattori M, Nangaku M. Novel CFHR2-CFHR1 Hybrid in C3 Glomerulopathy Identified by Genomic Structural Variation Analysis. Kidney Int Rep 2019;4:1759-62. [PMID: 31844814 DOI: 10.1016/j.ekir.2019.09.008] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Smith RJH, Appel GB, Blom AM, Cook HT, D'Agati VD, Fakhouri F, Fremeaux-Bacchi V, Józsi M, Kavanagh D, Lambris JD, Noris M, Pickering MC, Remuzzi G, de Córdoba SR, Sethi S, Van der Vlag J, Zipfel PF, Nester CM. C3 glomerulopathy - understanding a rare complement-driven renal disease. Nat Rev Nephrol 2019;15:129-43. [PMID: 30692664 DOI: 10.1038/s41581-018-0107-2] [Cited by in Crossref: 81] [Cited by in F6Publishing: 96] [Article Influence: 27.0] [Reference Citation Analysis]
12 Cserhalmi M, Papp A, Brandus B, Uzonyi B, Józsi M. Regulation of regulators: Role of the complement factor H-related proteins. Semin Immunol 2019;45:101341. [PMID: 31757608 DOI: 10.1016/j.smim.2019.101341] [Cited by in Crossref: 29] [Cited by in F6Publishing: 38] [Article Influence: 9.7] [Reference Citation Analysis]
13 Liu J, Li W, Zhao H. CFHR3 is a potential novel biomarker for hepatocellular carcinoma. J Cell Biochem 2020;121:2970-80. [DOI: 10.1002/jcb.29551] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
14 Kaartinen K, Safa A, Kotha S, Ratti G, Meri S. Complement dysregulation in glomerulonephritis. Semin Immunol 2019;45:101331. [PMID: 31711769 DOI: 10.1016/j.smim.2019.101331] [Cited by in Crossref: 9] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
15 Medjeral-Thomas NR, Moffitt H, Lomax-Browne HJ, Constantinou N, Cairns T, Cook HT, Pickering MC. Glomerular Complement Factor H-Related Protein 5 (FHR5) Is Highly Prevalent in C3 Glomerulopathy and Associated With Renal Impairment. Kidney Int Rep 2019;4:1387-400. [PMID: 31701048 DOI: 10.1016/j.ekir.2019.06.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
16 Zhao F, Afonso S, Lindner S, Hartmann A, Löschmann I, Nilsson B, Ekdahl KN, Weber LT, Habbig S, Schalk G, Kirschfink M, Zipfel PF, Skerka C. C3-Glomerulopathy Autoantibodies Mediate Distinct Effects on Complement C3- and C5-Convertases. Front Immunol 2019;10:1030. [PMID: 31214159 DOI: 10.3389/fimmu.2019.01030] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
17 Hu X, Liu H, Du J, Chen Y, Yang M, Xie Y, Chen J, Yan S, Ouyang S, Gong Z. The clinical significance of plasma CFHR 1-5 in lupus nephropathy. Immunobiology 2019;224:339-46. [PMID: 30975435 DOI: 10.1016/j.imbio.2019.03.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
18 Ng MSY, McClymont K, McCallum N, Dua R, Holman K, Bennetts B, Ho G, Patel C, Mallett AJ. CFHR5 Nephropathy in a Greek-Cypriot Australian Family: Ancestry-Informed Precision Medicine. Kidney Int Rep 2018;3:1222-8. [PMID: 30197990 DOI: 10.1016/j.ekir.2018.04.007] [Reference Citation Analysis]
19 van Beek AE, Kamp A, Kruithof S, Nieuwenhuys EJ, Wouters D, Jongerius I, Rispens T, Kuijpers TW, Gelderman KA. Reference Intervals of Factor H and Factor H-Related Proteins in Healthy Children. Front Immunol 2018;9:1727. [PMID: 30116238 DOI: 10.3389/fimmu.2018.01727] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
20 Goicoechea de Jorge E, López Lera A, Bayarri-Olmos R, Yebenes H, Lopez-Trascasa M, Rodríguez de Córdoba S. Common and rare genetic variants of complement components in human disease. Mol Immunol 2018;102:42-57. [PMID: 29914697 DOI: 10.1016/j.molimm.2018.06.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
21 Rudnick RB, Chen Q, Stea ED, Hartmann A, Papac-Milicevic N, Person F, Wiesener M, Binder CJ, Wiech T, Skerka C, Zipfel PF. FHR5 Binds to Laminins, Uses Separate C3b and Surface-Binding Sites, and Activates Complement on Malondialdehyde-Acetaldehyde Surfaces. J Immunol 2018;200:2280-90. [PMID: 29483359 DOI: 10.4049/jimmunol.1701641] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
22 Łukawska E, Polcyn-adamczak M, Niemir ZI. The role of the alternative pathway of complement activation in glomerular diseases. Clin Exp Med 2018;18:297-318. [DOI: 10.1007/s10238-018-0491-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 5.3] [Reference Citation Analysis]
23 Wong EKS, Kavanagh D. Diseases of complement dysregulation-an overview. Semin Immunopathol 2018;40:49-64. [PMID: 29327071 DOI: 10.1007/s00281-017-0663-8] [Cited by in Crossref: 45] [Cited by in F6Publishing: 51] [Article Influence: 11.3] [Reference Citation Analysis]
24 Cserhalmi M, Uzonyi B, Merle NS, Csuka D, Meusburger E, Lhotta K, Prohászka Z, Józsi M. Functional Characterization of the Disease-Associated N-Terminal Complement Factor H Mutation W198R. Front Immunol 2017;8:1800. [PMID: 29321782 DOI: 10.3389/fimmu.2017.01800] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
25 van Beek AE, Pouw RB, Brouwer MC, van Mierlo G, Geissler J, Ooijevaar-de Heer P, de Boer M, van Leeuwen K, Rispens T, Wouters D, Kuijpers TW. Factor H-Related (FHR)-1 and FHR-2 Form Homo- and Heterodimers, while FHR-5 Circulates Only As Homodimer in Human Plasma. Front Immunol 2017;8:1328. [PMID: 29093712 DOI: 10.3389/fimmu.2017.01328] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]